Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Biogen Inc.

(BGEN)

Cowen & Co. analyst David Stone maintained a "neutral" rating

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE